Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH is an independent, medium-sized, family-owned business based in Freiburg im Breisgau, Germany specialized in prescription drugs for gastroenterology and hepatology. Salofalk®, Budenofalk®, and Ursofalk® are currently its best-known medications. In addition to Germany, the company’s products are sold in a total of 65 countries.
Dr. Falk Pharma GmbH is a company that actively conducts research. With a focus on the future, Dr. Falk Pharma GmbH is working both to continually improve drugs that have already been approved (such as in the form of new formulations) and to research new active ingredients for the treatment of gastroenterological diseases. Among Falk’s promising development projects are norursodeoxycholic acid for the treatment of PSC and a budesonide tablet recently approved in Europe for the treatment of eosinophilic esophagitis. An overview of the large number of pharmaceutical advancements Dr. Falk Pharma GmbH is currently pursuing can be viewed at the following website: www.clinicaltrials.gov.
The events offered by the Falk Foundation e.V. enjoy an excellent reputation thanks to being highly scientific. The Falk Foundation e.V. was founded in 1978 by Dr. Dr. Herbert Falk to promote product independent, world-class training in the fields of gastroenterology and hepatology. The Falk Foundation e.V. continues to organize and support regional, national, and international congresses and training events and also offers an extensive literature and media service.
All of the activities of Dr. Falk Pharma GmbH and the Falk Foundation e.V. are characterized by a degree of constancy that has become rare these days. As a family-owned business, Falk does not focus on short-term success, but instead is committed to long-term collaboration and scientific assistance for both physicians and patients.
Further information can be found here.